Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH003 plus toripalimab in unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma
CTR20213230Phase 2Completed
- Sponsor
- Youhe Medical Technology
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ciltistotug and toripalimab in melanoma and pancreatic adenocarcinoma (PDAC) (3 cohorts), sponsored by Youhe Medical Technology. Primary endpoint: Objective response rate (ORR) by investigator assessment per RECIST 1.1. Started Dec 2021; status: completed.
02
Drugs
ciltistotugtoripalimab
03
Conditions
melanomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20213230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213230.